Joseph Karnish, DO
Family Medicine · Georgetown, DENPI 1427002690
Payments from drug & device makers
Across 123 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$311
- GSK$275
- AbbVie$237
- Pfizer$237
- AstraZeneca$222
- Astellas Pharma US Inc$200
- plus $689 from 14 others
What the payments were for
- Food & beverage$1,94990%
- Education$22210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 21 | $311 |
| GSK | 16 | $275 |
| AbbVie(2 entities) | 13 | $237 |
| Pfizer | 15 | $237 |
| AstraZeneca | 13 | $222 |
| Astellas Pharma US Inc | 2 | $200 |
| Novo Nordisk | 11 | $197 |
| Lilly USA, LLC | 9 | $136 |
| Johnson & Johnson | 4 | $66 |
| Biohaven Pharmaceuticals, Inc. | 4 | $56 |
| Merck | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $32 |
| Amgen | 2 | $30 |
| Exact Sciences | 1 | $28 |
| Dexcom, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
How this compares
$2,171 in reported general payments places this provider in the 80th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $155,926 |
| TrulicityDulaglutide | 55 | $106,145 |
| EliquisApixaban | 83 | $97,463 |
| XareltoRivaroxaban | 62 | $75,232 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $61,580 |
| JardianceEmpagliflozin | 37 | $60,718 |
| OxycontinOxycodone Hcl | 37 | $48,894 |
| MyrbetriqMirabegron | 44 | $43,752 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $40,891 |
| Nurtec OdtRimegepant Sulfate | 22 | $30,563 |
| MounjaroTirzepatide | 17 | $30,468 |
| LinzessLinaclotide | 24 | $29,348 |
| FarxigaDapagliflozin Propanediol | 20 | $27,927 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $21,607 |
| JanuviaSitagliptin Phosphate | 12 | $19,532 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $197 | $155,92691 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $136 | $136,61372 claims |
| PfizerEliquis, Nurtec Odt | $237 | $128,025105 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta | $311 | $99,26371 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $275 | $78,53096 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $222 | $75,80372 claims |
| Johnson & JohnsonXarelto | $66 | $75,23262 claims |
| Astellas Pharma US IncMyrbetriq | $200 | $43,75244 claims |
| MerckJanuvia, Belsomra | $46 | $35,07631 claims |
| AbbVieLinzess, Synthroid | $237 | $33,260107 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 352 family medicine providers in Delaware.
Other family medicine in Georgetown
- Dustin DavisGeorgetown$17K
- Eileen DavisGeorgetown$16K
- David KrasnerWilmington$110K
- Gregory PapaNew Castle$67K
- Sarah MullinsWilmington$36K
- Ashley PanichelliWilmington$27K
- David BirchMilford$24K
- Michelle PapaNewark$23K
- Maryann ConnorWilmington$21K
- Jill MackeyWilmington$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.